Answer: Our product is designed for industrial-scale applications and can support synthesis at the mmol level and beyond, meeting the needs of large-scale nucleic acid drug development and production.

Answer: The production cycle typically takes 4-5 weeks, depending on the specific requirements of the customer.

Answer: Our product achieves an initial synthesis purity of over 80%, whereas traditional CPG typically reaches only 60-80%. This advantage helps pharmaceutical companies significantly reduce purification costs and improve overall production efficiency.

Answer:
Our CPG solid supports offer significantly higher loading capacity compared to traditional solid supports.

For Unylinker-functionalized CPG, the typical loading capacities are:

• 500 Å: 200–240 μmol/g

• 1000 Å: 100–150 μmol/g

• 2000 Å: 40–80 μmol/g

For standard nucleoside supports (such as A, C, G, T, or U), the typical loading capacities are:

• 500 Å: 200–220 μmol/g

• 1000 Å: 100–110 μmol/g

• 2000 Å: 40–60 μmol/g

These higher loading levels help improve synthesis efficiency and overall productivity in oligonucleotide manufacturing.

Answer: Our new CPG architecture has a higher synthesis success rate for FLP compared to traditional chemically modified CPG. For example, for 25-26 base pair FLP, the success rate is over 85%.

Answer: No. Our Co-Polymer Coated CPG uses an ultra-thin resin coating, which retains the high load capacity of the resin while preventing the swelling issue commonly seen with traditional resin-based solid supports when heated, thanks to the stable physical structure of the glass particle pores.

Answer: Due to the resin coating on the surface, our CPG is one of the most suitable architectures for installing delivery systems. Compared to the physical limitations of traditional CPG surfaces, our product allows for efficient and direct installation of delivery systems.

Answer: Currently, we support a variety of delivery systems, including GalNAc, cholesterol, and more. We can also expand to meet additional customer-specific needs.

Yes. Our solid support features a reactive polystyrene layer with excellent chemical reactivity, allowing easy conjugation with a wide range of monomers, including standard nucleotides (A, C, G, T), GalNAc, unylinker, CPR, CPR II, and more.

The selection mainly depends on the length and flexibility of the oligonucleotide sequence. As a general guideline:

• 500Å CPG: recommended for 20–35 nt oligonucleotides

• 1000Å CPG: recommended for 50–80 nt sequences

• 1500Å CPG: recommended for 75–150 nt sequences

• 2000Å CPG: recommended for 100–150 nt long oligonucleotides

• 3000Å CPG: recommended for 150–200 nt long-chain oligonucleotides

Larger pore sizes provide better accessibility for longer and more flexible oligonucleotide chains, improving overall synthesis efficiency and yield.

Yes. We have conducted synthesis tests using our 2000Å Hyperlink CPG with UnyLinker (N-PH) on 175 nt oligonucleotide sequences and get perfect results. For additional experimental data and HPLC reports(like 81nt sequence synthesizing test report), please visit our Test Result Center for more details.